RHY 8.57% 6.4¢ rhythm biosciences limited

Volition RX is developing a molecular based blood test for...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 17 Posts.
    lightbulb Created with Sketch. 4

    Volition RX is developing a molecular based blood test for colorectal cancer.

    They are looking for early nucleosomic markers for cancer. Ala the nucleus of the cell / DNA.

    Molecular blood tests for bowel cancer (and there are others) are expensive.

    Colostat will be significantly cheaper and potentially funded by t

    he government. 

    Not many on the RHYTHM thread but expect some major fireworks later in the year and  2019. Its a 10 bagger from here.


 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.